Uni-Bio Science Group

Uni-Bio Science Group Net Margin

The Net Profit Margin of Uni-Bio Science Group (690.HK) as of Oct 15, 2026 is 14.97 %. In the previous year, Net Profit Margin was 14.62 % — a change of 2.37% (higher).

Net Margin

14.97 %

YoY

2.37%

Last updated:

Net Profit Margin of Uni-Bio Science Group is 2024 14.97 % . Net Profit Margin of Uni-Bio Science Group was 2023 14.62 % . It decreases by 2.37% higher compared to the previous year.

For Uni-Bio Science Group, the net margin of 15.0% is up versus -34.2% a few years ago.

The Uni-Bio Science Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-178.50 HKD
Jan 1, 2018
-102.45 HKD
Jan 1, 2019
1.17 HKD
Jan 1, 2020
-34.16 HKD
Jan 1, 2021
-5.54 HKD
Jan 1, 2022
8.75 HKD
Jan 1, 2023
14.62 HKD
Jan 1, 2024
14.97 HKD
The Uni-Bio Science Group Net Margin history
YEARNet MarginYoY
14.97 %+2.37%
14.62 %+67.18%
8.75 %-257.78%
-5.54 %-83.77%
-34.16 %-3,009.67%
1.17 %-101.15%
-102.45 %-42.61%
-178.50 %+369.22%
-38.04 %-21.52%
-48.47 %+4.86%
-46.23 %+1,195.54%
-3.57 %+328.91%
-0.83 %-53.92%
-1.81 %-25.14%
-2.41 %-21.35%
-3.07 %+217.47%
-0.97 %-523.46%
0.23 %+28.94%
0.18 %-139.59%
-0.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd, listed on the Hong Kong Stock Exchange under ticker 690.HK with ISIN KYG9198H1406, operates in the Health Care sector within the Biotechnology industry. The company, which completed its IPO on November 12, 2001, employs 340 full-time staff. Uni-Bio Science Group functions through four business segments. The In-house Chemical Pharmaceutical Products segment focuses on manufacturing and selling proprietary chemical pharmaceutical products, including the product named Pinapu. The In-house Biological Pharmaceutical Products segment handles the production and distribution of biological pharmaceutical products such as GeneTime and GeneSoft. The In-house Biological Pipeline segment is dedicated to advancing the industrialization of its biological pipeline, featuring products like Uni-E4 and Uni-PTH. The Third-party Pharmaceutical Products segment manages the sales of pharmaceutical products from external suppliers. The company's headquarters location is not publicly specified, and its official website is www.uni-bioscience.com. Uni-Bio Science Group's business model integrates in-house development with third-party product distribution, targeting both chemical and biological pharmaceutical markets. The company's operational structure reflects a diversified approach to pharmaceutical research, development, and commercialization, though specific details about its research pipeline, market reach, or financial performance are not provided in the available information. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

Net Profit Margin of Uni-Bio Science Group is 14.97 % in 2024.

Net Profit Margin of Uni-Bio Science Group changed from 14.62 % to 14.97 %, representing a 2.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group